Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Efficacy of 2nd-line treatment in CLL after venetoclax-based 1st-line treatment: Results from the GAIA/CLL13 trial

View Full Paper
Ask AI
Bookmark
Share

Authors

CNCarsten Utoft NiemannTTTamar TadmorMHMichael Hallek

Discussion

Loading...

Member takes

Overview

Trial reports efficacy of 2nd-line treatment for chronic lymphocytic leukemia, suggesting venetoclax retreatment is effective.

Key Points

  • To evaluate the efficacy of second-line treatment options for chronic lymphocytic leukemia after initial venetoclax-based therapy.
  • Analyzed 2nd-line treatment outcomes for 177 CLL patients from the GAIA/CLL13 trial
  • Treatment options include CIT, BTK inhibitor, venetoclax, and combinations between them
  • Tracked time to next treatment, treatment-free survival, and overall survival after 2nd-line treatment.
  • 2-year treatment-free survival rates: 90.5% for venetoclax-based and 92.4% for venetoclax + BTK inhibitor
  • 2-year overall survival rates: 100% for venetoclax-based and 91.3% for BTK inhibitor-based treatments
  • Primary outcomes support venetoclax-based therapy as a feasible option in relapsed CLL patients.

Cite This Study

Niemann et al. (2025) studied this question.

synapsesocial.com/papers/693624d44fa91c937236d069https://doi.org/10.1182/blood-2025-795
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Clinical experience and safety of venetoclax in the treatment of patients with chronic lymphocytic leukemia in second and subsequent lines of therapy: Real-world data fron hemato-oncology centers  of slovakia2025
  2. 2First-line venetoclax-based regimens versus chemoimmunotherapy in chronic lymphocytic leukemia: A real-world analysis from the brazilian CLL registry2025
  3. 3Efficacy of fixed-duration venetoclax-based regimens as first-line in chronic lymphocytic leukemia: A systematic review and meta-analysis of clinical trials2025
  4. 4Real-world treatment patterns and patient characteristics of venetoclax combination time-limited therapy for chronic lymphocytic leukemia2025
  5. 5Long term follow-up and results of retreatement after obinutuzumab-venetoclax in first-line CLL patients with coexisting conditions2025